Clinical Trial Update: A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations [Phase 2]

View source ↗

Summary

A phase 2 single-arm exploratory trial evaluating pemigatinib in HER2-negative advanced breast cancer with FGFR alterations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pemigatinib (pemigatinib)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Breast Cancer | Phase 2 | Status: UNKNOWN